Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
05:35pm, Wednesday, 12'th Jun 2024
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
07:20pm, Monday, 10'th Jun 2024
In the closing of the recent trading day, Astrazeneca (AZN) stood at $80.21, denoting a +0.24% change from the preceding trading day.
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
10:45am, Monday, 10'th Jun 2024
The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
07:00am, Monday, 10'th Jun 2024
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adul
The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now
04:13pm, Friday, 07'th Jun 2024
Today, we discuss three must-own stocks as major Wall Street indices reach new highs. The rise in share prices of technology stocks and supportive economic data hinting at potential Federal Reserve po
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
10:59am, Friday, 07'th Jun 2024
Drugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.
Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment
08:00am, Wednesday, 05'th Jun 2024
ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closi
We're in a difficult business but have the right level of confidence, says AstraZeneca CEO
07:45pm, Tuesday, 04'th Jun 2024
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
07:41pm, Tuesday, 04'th Jun 2024
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.
Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030
07:17pm, Tuesday, 04'th Jun 2024
In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade. AstraZeneca announced in late
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKV
AstraZeneca: ASCO feedback positive
04:58am, Tuesday, 04'th Jun 2024
Reaction to AstraZeneca PLC (LSE:AZN)'s presentations at the annual American Society of Clinical Oncology conference was broadly positive following of sessions with analysts and clinicians. Eye-catchi
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
07:16pm, Monday, 03'rd Jun 2024
In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.
Cramer's Stop Trading: AstraZeneca
10:46am, Monday, 03'rd Jun 2024
CNBC's Jim Cramer explains why he is keeping an eye on shares of AstraZeneca.
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
09:00am, Monday, 03'rd Jun 2024
Eli Lilly and Novo Nordisk aren't the only ones making anti-obesity drugs. Amgen, AstraZeneca, and Viking Therapeutics have credible candidates.
